Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 10/20 | 0.41 |
| ▸ | HTR2C | P28335 | 10/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10202192 | 0.90 | L3MBTL3 (0.37) | L3MBTL3HTR2AHTR2CNCF1L3MBTL1 | |
| SCHEMBL18843591 | 0.86 | L3MBTL3 (0.45) | L3MBTL3HTR2AHTR2CNCF1L3MBTL1 | |
| SCHEMBL172592 | 0.83 | — | — | |
| SCHEMBL172541 | 0.83 | — | — | |
| SCHEMBL81996 | 0.83 | — | — | |
| SCHEMBL8442130 | 0.82 | HTR2A (0.41) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| SCHEMBL24319367 | 0.81 | NCF1 (0.42) | NCF1KDM4EALDH1A1 | |
| SCHEMBL17888490 | 0.80 | HTR2A (0.40) | HTR2AHTR2CNCF1L3MBTL1MEN1 | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL9782767 | 0.79 | ADH1C (0.38) | L3MBTL3HTR2AHTR2CL3MBTL1ALDH1A1 | |
| SCHEMBL20614488 | 0.79 | NCF1 (0.42) | HTR2AHTR2CNCF1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2768891-B1 | FIBRE REINFORCED POLYISOCYANURATE COMPONENT AND METHOD FOR ITS PRODUCTION | COVESTRO DEUTSCHLAND AG (DE) | 2018-08-08 | — | — | EP | claimed |
| US-20160288377-A1 | METHOD FOR PRODUCING COMPOSITE COMPONENTS | COVESTRO DEUTSCHLAND AG (DE) | 2016-10-06 | — | — | US | claimed |
| EP-2920220-A1 | METHOD FOR PRODUCING COMPOSITE COMPONENTS | Bayer Materialscience AG (DE) | 2015-09-23 | — | — | EP | claimed |
| CN-104768993-A | Method for producing composite components | BAYER MATERIALSCIENCE AG | 2015-07-08 | — | — | CN | claimed |
| US-20150125703-A1 | FIBER-REINFORCED POLYISOCYANURATE COMPONENT AND A METHOD FOR PRODUCTION THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-07 | — | — | US | claimed |
| EP-2768891-A1 | FIBRE-REINFORCED POLYISOCYANURATE COMPONENT AND A METHOD FOR PRODUCTION THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-08-27 | — | — | EP | claimed |
| CN-103890059-A | FIBRE-REINFORCED POLYISOCYANURATE COMPONENT AND A METHOD FOR PRODUCTION THEREOF | BAYER IP GMBH | 2014-06-25 | — | — | CN | claimed |
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2014-06-19 | — | — | US | claimed |
| WO-2014076022-A1 | METHOD FOR PRODUCING COMPOSITE COMPONENTS | BAYER MATERIALSCIENCE AG (DE) | 2014-05-22 | — | — | WO | claimed |
| EP-2725024-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2014-04-30 | — | — | EP | claimed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | claimed |
| WO-2005021533-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. | 2005-03-10 | — | — | US | claimed |
| WO-2005021532-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | AMGEN INC. | 2005-03-03 | — | — | US | claimed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | claimed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | claimed |
| US-5977102-A | INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES OR EPIDERMAL GROWTH FACTOR; ANTITUMOR,-CARCINOGENIC, -METASTASIS,-PROLIFERATION AGENTS AND -INFLAMMATORY AGENTS; PSORIASIS; ANGIOGENESIS INHIBITORS; IMMUNOLOGY; | DR. KARL THOMAE GMBH (DE) | 1999-11-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | L3MBTL3 2540/4885HTR2A 2028/4885HTR2C 1475/4885 |
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | PLA2G5, LTA4H, PLA2G4A | L3MBTL3 4850/4885HTR2A 2578/4885HTR2C 2105/4885 |
| US-20050049253-A1 | Substituted quinolinone derivatives and methods of use | NQO1, NQO2, UGT1A1 | L3MBTL3 3444/4885HTR2A 2463/4885HTR2C 2194/4885 |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | L3MBTL3 2820/4885HTR2A 3297/4885HTR2C 2453/4885 |
| US-20050054670-A1 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | VHL, DPYD, UGT1A1 | L3MBTL3 2161/4885HTR2A 3196/4885HTR2C 2739/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | L3MBTL3 2661/4885HTR2A 2228/4885HTR2C 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.